Disparity between angiographic regression and clinical event rates with hydrophobic statins
- 1 June 2002
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 359 (9324), 2195-2198
- https://doi.org/10.1016/s0140-6736(02)09098-0
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-IJournal of Clinical Investigation, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical eventsJournal of the American College of Cardiology, 1995
- Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)The American Journal of Cardiology, 1995
- Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)The Lancet, 1994
- Influences of Pravastatin and Simvastatin, HMG-CoA Reductase Inhibitors, on Myocardial Stunning in DogsJournal of Cardiovascular Pharmacology, 1993
- Regulation of the mevalonate pathwayNature, 1990
- In vitro and in vivo synthesis of dolichol and other main mevalonate products in various organs of the ratEuropean Journal of Biochemistry, 1987